相似文献
1
UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies.
Can Urol Assoc J. 2022 Aug;16(8):E416-E431. doi: 10.5489/cuaj.8054.
2
UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies Summary of changes.
Can Urol Assoc J. 2022 Aug;16(8):243-244. doi: 10.5489/cuaj.8007.
3
Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies.
Can Urol Assoc J. 2021 Jun;15(6):E307-E322. doi: 10.5489/cuaj.7355.
4
Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies - Executive summary.
Can Urol Assoc J. 2021 Jun;15(6):159-161. doi: 10.5489/cuaj.7357.
5
Qualitative Review of Clinical Guidelines for Medical and Surgical Management of Urolithiasis: Consensus and Controversy 2020.
J Urol. 2021 Apr;205(4):999-1008. doi: 10.1097/JU.0000000000001478. Epub 2020 Dec 7.
6
The American Urological Association 2003 guideline on management of benign prostatic hyperplasia: a Canadian opinion.
Can J Urol. 2004 Apr;11(2):2186-93.
7
UPDATE - Canadian Urological Association guideline: Evaluation and medical management of kidney stones.
Can Urol Assoc J. 2022 Jun;16(6):175-188. doi: 10.5489/cuaj.7872.
8
UPDATE - 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) castration-resistant prostate cancer (CRPC) guideline: What has changed since 2019?
Can Urol Assoc J. 2021 Feb;15(2):11-12. doi: 10.5489/cuaj.7160.
9
Management of the side effects of androgen deprivation therapy in men with prostate cancer.
Expert Opin Pharmacother. 2008 Nov;9(16):2829-41. doi: 10.1517/14656566.9.16.2829.
10
UPDATE - Canadian Urological Association guideline: Male lower urinary tract symptoms/benign prostatic hyperplasia.
Can Urol Assoc J. 2022 Aug;16(8):245-256. doi: 10.5489/cuaj.7906.
引用本文的文献
1
Taiwan Consensus for the Management of Cardiovascular Risks and Complications in Patients with Prostate Cancer.
Acta Cardiol Sin. 2025 May;41(3):288-310. doi: 10.6515/ACS.202505_41(3).20250224A.
2
Management of vasomotor symptoms in cancer patients.
Oncologist. 2025 Feb 6;30(2). doi: 10.1093/oncolo/oyaf002.
3
Screening and management of metabolic, cardiac, and bone health in prostate cancer patients on androgen deprivation therapy A survey of specialized physicians.
Can Urol Assoc J. 2024 Jun;18(6):212-215. doi: 10.5489/cuaj.8687.
4
Cardiologist-Performed Baseline Evaluation with an Assessment of Coronary Status for Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: Impact on Newly Diagnosed Coronary Artery Disease.
Cancers (Basel). 2023 Aug 17;15(16):4157. doi: 10.3390/cancers15164157.
5
Insights Into the Cardiomodulatory Effects of Sex Hormones: Implications in Transgender Care.
Hypertension. 2023 Sep;80(9):1810-1820. doi: 10.1161/HYPERTENSIONAHA.123.19501. Epub 2023 Jul 18.
本文引用的文献
1
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
Circulation. 2021 Oct 19;144(16):1295-1307. doi: 10.1161/CIRCULATIONAHA.121.056810. Epub 2021 Aug 30.
2
2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.
Can J Cardiol. 2021 Aug;37(8):1129-1150. doi: 10.1016/j.cjca.2021.03.016. Epub 2021 Mar 26.
3
2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).
Can Urol Assoc J. 2021 Feb;15(2):E81-E90. doi: 10.5489/cuaj.7074.
4
The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.
J Urol. 2021 Jan;205(1):60-67. doi: 10.1097/JU.0000000000001341. Epub 2020 Aug 28.
5
Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician.
Eur Urol Focus. 2020 Nov 15;6(6):1170-1179. doi: 10.1016/j.euf.2020.05.014. Epub 2020 Jul 18.
6
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29.
7
Neoadjuvant Leuprolide Therapy with Radical Prostatectomy: Long-term Effects on Health-related Quality of Life.
Eur Urol Focus. 2021 Jul;7(4):779-787. doi: 10.1016/j.euf.2020.03.001. Epub 2020 Mar 9.
8
Bone Health and Bone-Targeted Therapies for Prostate Cancer: American Society of Clinical Oncology Endorsement Summary of a Cancer Care Ontario Guideline.
JCO Oncol Pract. 2020 Jul;16(7):389-393. doi: 10.1200/JOP.19.00778. Epub 2020 Feb 19.
9
Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable.
Med Sci Sports Exerc. 2019 Nov;51(11):2375-2390. doi: 10.1249/MSS.0000000000002116.
10
Responsiveness to Resistance-Based Multimodal Exercise Among Men With Prostate Cancer Receiving Androgen Deprivation Therapy.
J Natl Compr Canc Netw. 2019 Oct 1;17(10):1211-1220. doi: 10.6004/jnccn.2019.7311.
Zotero 插件